Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Karyopharm Therapeutics (KPTI) Net Margin (2016 - 2025)

Karyopharm Therapeutics (KPTI) has disclosed Net Margin for 14 consecutive years, with 87.41% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Net Margin rose 4648.0% year-over-year to 87.41%, compared with a TTM value of 91.57% through Dec 2025, down 2937.0%, and an annual FY2025 reading of 2.5%, down 252.0% over the prior year.
  • Net Margin was 87.41% for Q4 2025 at Karyopharm Therapeutics, down from 58.37% in the prior quarter.
  • Across five years, Net Margin topped out at 55.61% in Q2 2024 and bottomed at 246.84% in Q1 2021.
  • Average Net Margin over 5 years is 103.88%, with a median of 98.16% recorded in 2022.
  • The sharpest move saw Net Margin soared 15999bps in 2022, then tumbled -14789bps in 2025.
  • Year by year, Net Margin stood at 30.66% in 2021, then plummeted by -474bps to 114.76% in 2022, then fell by -9bps to 124.64% in 2023, then decreased by -7bps to 133.89% in 2024, then soared by 35bps to 87.41% in 2025.
  • Business Quant data shows Net Margin for KPTI at 87.41% in Q4 2025, 58.37% in Q3 2025, and 92.28% in Q2 2025.